speb/financial-data huggingface dataset:
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -902000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -1427000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: -625000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 610000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Change In Payable: 1333000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Change In Receivables: 3860000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: 6455000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Changes In Cash: -159000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Common Stock: 358000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 358000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 92211000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 92211000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Common Stock Issuance: 0.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 2937000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 2937000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 6905000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 1547000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Current Assets: 50523000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 50523000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 33000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 33000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Current Debt: 6064000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 6064000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 6097000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 6097000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 16809000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 16809000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 3502000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 3502000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Depreciation: 2066000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 2066000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 2066000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 504000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 2066000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 504000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 179077540.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 14.96
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 14185000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 2679000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Dividends Received Cfi: 373000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — EBIT: 15275000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — EBIT: 1550000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — EBITDA: 17341000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — EBITDA: 2054000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: 948000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — End Cash Position: 1989000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: 2975000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 13772000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -28000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: 251000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Goodwill: 630000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 630000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 2573000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 2573000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 28391000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 28391000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Gross Profit: 33878000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 5844000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Interest Expense: 367000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 109000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 367000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 109000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -359000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 2475000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Inventory: 9085000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 9085000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 99275000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 99275000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -20817000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 3352000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 3352000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 0.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Issuance Of Debt: 4000000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 42000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 42000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Debt: 1000000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 1000000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 1042000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 1042000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Long Term Debt Issuance: 4000000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Equity Investment: 22757000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 22757000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 618000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 618000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Minority Interest: 0.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: 0.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Minority Interests: 0.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Minority Interests: -11000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Net Business Purchase And Sale: -20868000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 0.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Net Debt: 5075000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Net Debt: 5075000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -133000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Net Income: 14185000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income: 2679000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 14185000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 2679000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 14185000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 2690000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 14185000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 2679000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 14185000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 2679000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 14908000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 14185000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 2690000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Net Intangibles Purchase And Sale: -28000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Net Interest Income: -367000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -109000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: 3413000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: 4260000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: 4000000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: -367000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -109000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: -2309000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Net PPE: 28391000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 28391000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -3869000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Net Short Term Debt Issuance: 260000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 89638000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 89638000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 2326000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 2326000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 2000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 2000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 17341000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 2054000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Normalized Income: 14185000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 2679000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 17683000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Operating Income: 12299000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Operating Income: 772000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Operating Revenue: 40783000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 7391000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 179109870.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 179109870.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: 3819000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 3819000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 1731000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 1731000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 91853000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 91853000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 1943000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 1943000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: -1948000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 699000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 699000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 2976000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 778000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 12641000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 2983000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Other Properties: 25454000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 25454000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 98000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 98000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 26720000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 26720000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Payables: 4098000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Payables: 4098000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Pretax Income: 14908000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 1441000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: 78000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of Business: -20868000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of Intangibles: -28000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -57399000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -3883000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 6905000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 1547000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 2066000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 504000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Sale Of Intangibles: 0.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 60812000000.00
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 14000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Share Issued: 179109870.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 179109870.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 92211000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 92211000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 89638000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 89638000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Tax Provision: 1189000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Tax Provision: -892000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.08
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.40
NATCOPHARM.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -3977000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Total Assets: 110737000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 110737000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 93211000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 93211000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Total Debt: 7139000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 7139000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 92211000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 92211000000.00
NATCOPHARM.NS income_statement (annual, 2026-03-31) — Total Expenses: 28484000000.00
NATCOPHARM.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 6619000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 18526000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 18526000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 60214000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 60214000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 1717000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 1717000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 5000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 5000000.00
NATCOPHARM.NS balance_sheet (annual, 2026-03-31) — Working Capital: 33714000000.00
NATCOPHARM.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 33714000000.00
NATH income_statement (annual, 2022-03-31) — +Operating Expense: 14199000.00
NATH income_statement (annual, 2022-03-31) — +Total Revenue: 114882000.00
NATH balance_sheet (annual, 2022-03-31) — Accounts Payable: 6381000.00
NATH balance_sheet (annual, 2022-03-31) — Accounts Receivable: 13241000.00
NATH balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -10344000.00
NATH balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 62307000.00
NATH income_statement (annual, 2022-03-31) — Basic Average Shares: 4115000.00
NATH income_statement (annual, 2022-03-31) — Basic EPS: 3.30
NATH cash_flow (annual, 2022-03-31) — Beginning Cash Position: 81064000.00
NATH balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 1402000.00
NATH cash_flow (annual, 2022-03-31) — Capital Expenditure: -636000.00
NATH balance_sheet (annual, 2022-03-31) — Capital Lease Obligations: 8336000.00
NATH balance_sheet (annual, 2022-03-31) — Capital Stock: 94000.00
NATH balance_sheet (annual, 2022-03-31) — Cash And Cash Equivalents: 50063000.00
NATH balance_sheet (annual, 2022-03-31) — Cash Cash Equivalents And Short Term Investments: 50063000.00
NATH cash_flow (annual, 2022-03-31) — Cash Dividends Paid: -6173000.00
NATH balance_sheet (annual, 2022-03-31) — Cash Financial: 50063000.00
NATH cash_flow (annual, 2022-03-31) — Cash Flow From Continuing Financing Activities: -46842000.00
NATH cash_flow (annual, 2022-03-31) — Cash Flow From Continuing Investing Activities: -636000.00
NATH cash_flow (annual, 2022-03-31) — Cash Flow From Continuing Operating Activities: 16477000.00
NATH cash_flow (annual, 2022-03-31) — Change In Account Payable: 1695000.00
NATH cash_flow (annual, 2022-03-31) — Change In Inventory: 102000.00
NATH cash_flow (annual, 2022-03-31) — Change In Other Current Assets: 133000.00
NATH cash_flow (annual, 2022-03-31) — Change In Other Current Liabilities: -100000.00
NATH cash_flow (annual, 2022-03-31) — Change In Other Working Capital: 324000.00
NATH cash_flow (annual, 2022-03-31) — Change In Payable: 1695000.00
NATH cash_flow (annual, 2022-03-31) — Change In Payables And Accrued Expense: 1695000.00
NATH cash_flow (annual, 2022-03-31) — Change In Prepaid Assets: -116000.00
NATH cash_flow (annual, 2022-03-31) — Change In Receivables: -1908000.00
NATH cash_flow (annual, 2022-03-31) — Change In Working Capital: 130000.00
NATH cash_flow (annual, 2022-03-31) — Changes In Cash: -31001000.00
NATH balance_sheet (annual, 2022-03-31) — Common Stock: 94000.00
NATH cash_flow (annual, 2022-03-31) — Common Stock Dividend Paid: -6173000.00
NATH balance_sheet (annual, 2022-03-31) — Common Stock Equity: -54988000.00
NATH cash_flow (annual, 2022-03-31) — Common Stock Payments: 0.00
NATH balance_sheet (annual, 2022-03-31) — Construction In Progress: 112000.00
NATH income_statement (annual, 2022-03-31) — Cost Of Revenue: 70820000.00
NATH balance_sheet (annual, 2022-03-31) — Current Accrued Expenses: 6520000.00
NATH balance_sheet (annual, 2022-03-31) — Current Assets: 65400000.00
NATH balance_sheet (annual, 2022-03-31) — Current Capital Lease Obligation: 1849000.00
NATH balance_sheet (annual, 2022-03-31) — Current Debt And Capital Lease Obligation: 1849000.00
NATH balance_sheet (annual, 2022-03-31) — Current Deferred Liabilities: 1225000.00
NATH balance_sheet (annual, 2022-03-31) — Current Deferred Revenue: 876000.00
NATH balance_sheet (annual, 2022-03-31) — Current Liabilities: 16412000.00
NATH cash_flow (annual, 2022-03-31) — Deferred Income Tax: -444000.00
NATH cash_flow (annual, 2022-03-31) — Deferred Tax: -444000.00
NATH cash_flow (annual, 2022-03-31) — Depreciation Amortization Depletion: 1054000.00
NATH income_statement (annual, 2022-03-31) — Depreciation Amortization Depletion Income Statement: 1054000.00
NATH cash_flow (annual, 2022-03-31) — Depreciation And Amortization: 1054000.00
NATH income_statement (annual, 2022-03-31) — Depreciation And Amortization In Income Statement: 1054000.00
NATH income_statement (annual, 2022-03-31) — Diluted Average Shares: 4115000.00
NATH income_statement (annual, 2022-03-31) — Diluted EPS: 3.30
NATH income_statement (annual, 2022-03-31) — Diluted NI Availto Com Stockholders: 13596000.00
NATH income_statement (annual, 2022-03-31) — EBIT: 28671000.00
NATH income_statement (annual, 2022-03-31) — EBITDA: 29725000.00
NATH cash_flow (annual, 2022-03-31) — End Cash Position: 50063000.00
NATH cash_flow (annual, 2022-03-31) — Financing Cash Flow: -46842000.00
NATH cash_flow (annual, 2022-03-31) — Free Cash Flow: 15841000.00
NATH cash_flow (annual, 2022-03-31) — Gain Loss On Sale Of PPE: 0.00
NATH income_statement (annual, 2022-03-31) — General And Administrative Expense: 13145000.00
NATH balance_sheet (annual, 2022-03-31) — Goodwill: 95000.00
NATH balance_sheet (annual, 2022-03-31) — Goodwill And Other Intangible Assets: 1138000.00
NATH balance_sheet (annual, 2022-03-31) — Gross PPE: 21545000.00
NATH income_statement (annual, 2022-03-31) — Gross Profit: 44062000.00
NATH cash_flow (annual, 2022-03-31) — Income Tax Paid Supplemental Data: 4981000.00
NATH balance_sheet (annual, 2022-03-31) — Income Tax Payable: 103000.00
NATH income_statement (annual, 2022-03-31) — Interest Expense: 10135000.00
NATH income_statement (annual, 2022-03-31) — Interest Expense Non Operating: 10135000.00
NATH income_statement (annual, 2022-03-31) — Interest Income: 110000.00
NATH income_statement (annual, 2022-03-31) — Interest Income Non Operating: 110000.00
NATH cash_flow (annual, 2022-03-31) — Interest Paid Supplemental Data: 10563000.00
NATH balance_sheet (annual, 2022-03-31) — Interest Payable: 2968000.00
NATH balance_sheet (annual, 2022-03-31) — Inventory: 522000.00
NATH balance_sheet (annual, 2022-03-31) — Invested Capital: 53195000.00
NATH cash_flow (annual, 2022-03-31) — Investing Cash Flow: -636000.00
NATH balance_sheet (annual, 2022-03-31) — Land And Improvements: 123000.00
NATH balance_sheet (annual, 2022-03-31) — Leases: 7261000.00
NATH balance_sheet (annual, 2022-03-31) — Long Term Capital Lease Obligation: 6487000.00
NATH balance_sheet (annual, 2022-03-31) — Long Term Debt: 108183000.00
NATH balance_sheet (annual, 2022-03-31) — Long Term Debt And Capital Lease Obligation: 114670000.00
NATH balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 5231000.00
NATH cash_flow (annual, 2022-03-31) — Net Common Stock Issuance: 0.00
NATH balance_sheet (annual, 2022-03-31) — Net Debt: 58120000.00
NATH income_statement (annual, 2022-03-31) — Net Income: 13596000.00
NATH income_statement (annual, 2022-03-31) — Net Income Common Stockholders: 13596000.00
NATH income_statement (annual, 2022-03-31) — Net Income Continuous Operations: 13596000.00
NATH income_statement (annual, 2022-03-31) — Net Income From Continuing And Discontinued Operation: 13596000.00
NATH income_statement (annual, 2022-03-31) — Net Income From Continuing Operation Net Minority Interest: 13596000.00
NATH cash_flow (annual, 2022-03-31) — Net Income From Continuing Operations: 13596000.00
NATH income_statement (annual, 2022-03-31) — Net Income Including Noncontrolling Interests: 13596000.00
NATH income_statement (annual, 2022-03-31) — Net Interest Income: -10025000.00
NATH income_statement (annual, 2022-03-31) — Net Non Operating Interest Income Expense: -10025000.00
NATH cash_flow (annual, 2022-03-31) — Net Other Financing Charges: -40669000.00
NATH balance_sheet (annual, 2022-03-31) — Net PPE: 11201000.00
NATH cash_flow (annual, 2022-03-31) — Net PPE Purchase And Sale: -636000.00
NATH balance_sheet (annual, 2022-03-31) — Net Tangible Assets: -56126000.00
NATH balance_sheet (annual, 2022-03-31) — Non Current Deferred Assets: 582000.00
NATH balance_sheet (annual, 2022-03-31) — Non Current Deferred Liabilities: 1748000.00
NATH balance_sheet (annual, 2022-03-31) — Non Current Deferred Taxes Assets: 582000.00
NATH balance_sheet (annual, 2022-03-31) — Non Current Deferred Taxes Liabilities: 674000.00
NATH income_statement (annual, 2022-03-31) — Normalized EBITDA: 31079000.00
NATH income_statement (annual, 2022-03-31) — Normalized Income: 14588482.00
NATH cash_flow (annual, 2022-03-31) — Operating Cash Flow: 16477000.00
NATH cash_flow (annual, 2022-03-31) — Operating Gains Losses: 1354000.00
NATH income_statement (annual, 2022-03-31) — Operating Income: 29863000.00
NATH income_statement (annual, 2022-03-31) — Operating Revenue: 114882000.00
NATH balance_sheet (annual, 2022-03-31) — Ordinary Shares Number: 4115154.00
NATH balance_sheet (annual, 2022-03-31) — Other Current Assets: 390000.00
NATH balance_sheet (annual, 2022-03-31) — Other Current Liabilities: 295000.00
NATH income_statement (annual, 2022-03-31) — Other Gand A: 13145000.00
NATH income_statement (annual, 2022-03-31) — Other Income Expense: -1302000.00
NATH balance_sheet (annual, 2022-03-31) — Other Intangible Assets: 1043000.00
NATH cash_flow (annual, 2022-03-31) — Other Non Cash Items: 527000.00
NATH balance_sheet (annual, 2022-03-31) — Other Non Current Assets: 195000.00
NATH balance_sheet (annual, 2022-03-31) — Other Non Current Liabilities: 674000.00
NATH income_statement (annual, 2022-03-31) — Other Non Operating Income Expenses: 52000.00
NATH balance_sheet (annual, 2022-03-31) — Other Properties: 7416000.00
NATH balance_sheet (annual, 2022-03-31) — Other Receivables: 391000.00
NATH income_statement (annual, 2022-03-31) — Other Special Charges: 1354000.00
NATH balance_sheet (annual, 2022-03-31) — Payables: 6523000.00
NATH balance_sheet (annual, 2022-03-31) — Payables And Accrued Expenses: 13043000.00
NATH balance_sheet (annual, 2022-03-31) — Prepaid Assets: 980000.00
NATH income_statement (annual, 2022-03-31) — Pretax Income: 18536000.00
NATH balance_sheet (annual, 2022-03-31) — Properties: 0.00
NATH cash_flow (annual, 2022-03-31) — Provisionand Write Offof Assets: 186000.00
NATH cash_flow (annual, 2022-03-31) — Purchase Of PPE: -636000.00
NATH balance_sheet (annual, 2022-03-31) — Receivables: 13445000.00
NATH balance_sheet (annual, 2022-03-31) — Receivables Adjustments Allowances: -258000.00
NATH income_statement (annual, 2022-03-31) — Reconciled Cost Of Revenue: 70820000.00
NATH income_statement (annual, 2022-03-31) — Reconciled Depreciation: 1054000.00
NATH cash_flow (annual, 2022-03-31) — Repurchase Of Capital Stock: 0.00
NATH balance_sheet (annual, 2022-03-31) — Retained Earnings: -32619000.00
NATH cash_flow (annual, 2022-03-31) — Sale Of PPE: 0.00
NATH income_statement (annual, 2022-03-31) — Selling General And Administration: 13145000.00
NATH balance_sheet (annual, 2022-03-31) — Share Issued: 9369235.00
NATH income_statement (annual, 2022-03-31) — Special Income Charges: -1354000.00
NATH cash_flow (annual, 2022-03-31) — Stock Based Compensation: 74000.00
NATH balance_sheet (annual, 2022-03-31) — Stockholders Equity: -54988000.00
NATH balance_sheet (annual, 2022-03-31) — Tangible Book Value: -56126000.00
NATH income_statement (annual, 2022-03-31) — Tax Effect Of Unusual Items: -361518.00
NATH income_statement (annual, 2022-03-31) — Tax Provision: 4940000.00
NATH income_statement (annual, 2022-03-31) — Tax Rate For Calcs: 0.27
NATH balance_sheet (annual, 2022-03-31) — Taxes Receivable: 71000.00
NATH balance_sheet (annual, 2022-03-31) — Total Assets: 78516000.00
NATH balance_sheet (annual, 2022-03-31) — Total Capitalization: 53195000.00
NATH balance_sheet (annual, 2022-03-31) — Total Debt: 116519000.00
NATH balance_sheet (annual, 2022-03-31) — Total Equity Gross Minority Interest: -54988000.00
NATH income_statement (annual, 2022-03-31) — Total Expenses: 85019000.00
NATH balance_sheet (annual, 2022-03-31) — Total Liabilities Net Minority Interest: 133504000.00
NATH balance_sheet (annual, 2022-03-31) — Total Non Current Assets: 13116000.00
NATH balance_sheet (annual, 2022-03-31) — Total Non Current Liabilities Net Minority Interest: 117092000.00
NATH income_statement (annual, 2022-03-31) — Total Operating Income As Reported: 29863000.00
NATH balance_sheet (annual, 2022-03-31) — Total Tax Payable: 142000.00
NATH income_statement (annual, 2022-03-31) — Total Unusual Items: -1354000.00
NATH income_statement (annual, 2022-03-31) — Total Unusual Items Excluding Goodwill: -1354000.00
NATH balance_sheet (annual, 2022-03-31) — Treasury Shares Number: 5254081.00
NATH balance_sheet (annual, 2022-03-31) — Treasury Stock: 84770000.00
NATH balance_sheet (annual, 2022-03-31) — Working Capital: 48988000.00
NATH income_statement (annual, 2023-03-31) — +Operating Expense: 15196000.00
NATH income_statement (annual, 2023-03-31) — +Total Revenue: 130785000.00
NATH balance_sheet (annual, 2023-03-31) — Accounts Payable: 6461000.00
NATH balance_sheet (annual, 2023-03-31) — Accounts Receivable: 14923000.00
NATH balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -10871000.00
NATH balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 62565000.00
NATH income_statement (annual, 2023-03-31) — Basic Average Shares: 4089000.00
NATH income_statement (annual, 2023-03-31) — Basic EPS: 4.80
NATH cash_flow (annual, 2023-03-31) — Beginning Cash Position: 50063000.00
NATH balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 1414000.00
NATH cash_flow (annual, 2023-03-31) — Capital Expenditure: -626000.00
NATH balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 7188000.00
NATH balance_sheet (annual, 2023-03-31) — Capital Stock: 94000.00
NATH balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 29861000.00
NATH balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 29861000.00
NATH cash_flow (annual, 2023-03-31) — Cash Dividends Paid: -7563000.00
NATH balance_sheet (annual, 2023-03-31) — Cash Financial: 29861000.00
NATH cash_flow (annual, 2023-03-31) — Cash Flow From Continuing Financing Activities: -39455000.00
NATH cash_flow (annual, 2023-03-31) — Cash Flow From Continuing Investing Activities: -584000.00
NATH cash_flow (annual, 2023-03-31) — Cash Flow From Continuing Operating Activities: 19837000.00
NATH cash_flow (annual, 2023-03-31) — Change In Account Payable: 377000.00
NATH cash_flow (annual, 2023-03-31) — Change In Inventory: -17000.00
NATH cash_flow (annual, 2023-03-31) — Change In Other Current Assets: 27000.00
NATH cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: 63000.00
NATH cash_flow (annual, 2023-03-31) — Change In Other Working Capital: -489000.00
NATH cash_flow (annual, 2023-03-31) — Change In Payable: 377000.00
NATH cash_flow (annual, 2023-03-31) — Change In Payables And Accrued Expense: 377000.00
NATH cash_flow (annual, 2023-03-31) — Change In Prepaid Assets: -454000.00
NATH cash_flow (annual, 2023-03-31) — Change In Receivables: -2149000.00
NATH cash_flow (annual, 2023-03-31) — Change In Working Capital: -2642000.00
NATH cash_flow (annual, 2023-03-31) — Changes In Cash: -20202000.00
NATH balance_sheet (annual, 2023-03-31) — Common Stock: 94000.00
NATH cash_flow (annual, 2023-03-31) — Common Stock Dividend Paid: -7563000.00
NATH balance_sheet (annual, 2023-03-31) — Common Stock Equity: -44562000.00
NATH cash_flow (annual, 2023-03-31) — Common Stock Payments: -1892000.00
NATH balance_sheet (annual, 2023-03-31) — Construction In Progress: 63000.00
NATH income_statement (annual, 2023-03-31) — Cost Of Revenue: 81144000.00
NATH balance_sheet (annual, 2023-03-31) — Current Accrued Expenses: 6420000.00
NATH balance_sheet (annual, 2023-03-31) — Current Assets: 47361000.00
NATH balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 1782000.00
NATH balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 1782000.00
NATH balance_sheet (annual, 2023-03-31) — Current Deferred Liabilities: 1742000.00
NATH balance_sheet (annual, 2023-03-31) — Current Deferred Revenue: 1406000.00
NATH balance_sheet (annual, 2023-03-31) — Current Liabilities: 16709000.00
NATH cash_flow (annual, 2023-03-31) — Deferred Income Tax: 207000.00
NATH cash_flow (annual, 2023-03-31) — Deferred Tax: 207000.00
NATH cash_flow (annual, 2023-03-31) — Depreciation Amortization Depletion: 1135000.00
NATH income_statement (annual, 2023-03-31) — Depreciation Amortization Depletion Income Statement: 1135000.00
NATH cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 1135000.00
NATH income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 1135000.00
NATH income_statement (annual, 2023-03-31) — Diluted Average Shares: 4090000.00
NATH income_statement (annual, 2023-03-31) — Diluted EPS: 4.80
NATH income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: 19623000.00
NATH income_statement (annual, 2023-03-31) — EBIT: 34546000.00
NATH income_statement (annual, 2023-03-31) — EBITDA: 35681000.00
NATH cash_flow (annual, 2023-03-31) — End Cash Position: 29861000.00
NATH cash_flow (annual, 2023-03-31) — Financing Cash Flow: -39455000.00
NATH cash_flow (annual, 2023-03-31) — Free Cash Flow: 19211000.00
NATH cash_flow (annual, 2023-03-31) — Gain Loss On Sale Of PPE: 87000.00
NATH income_statement (annual, 2023-03-31) — General And Administrative Expense: 14061000.00
NATH balance_sheet (annual, 2023-03-31) — Goodwill: 95000.00
NATH balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 964000.00
NATH balance_sheet (annual, 2023-03-31) — Gross PPE: 20613000.00
NATH income_statement (annual, 2023-03-31) — Gross Profit: 49641000.00
NATH cash_flow (annual, 2023-03-31) — Income Tax Paid Supplemental Data: 7160000.00
NATH balance_sheet (annual, 2023-03-31) — Income Tax Payable: 0.00
NATH income_statement (annual, 2023-03-31) — Interest Expense: 7742000.00
NATH income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 7742000.00
NATH income_statement (annual, 2023-03-31) — Interest Income: 440000.00
NATH income_statement (annual, 2023-03-31) — Interest Income Non Operating: 440000.00
NATH cash_flow (annual, 2023-03-31) — Interest Paid Supplemental Data: 8061000.00
NATH balance_sheet (annual, 2023-03-31) — Interest Payable: 2143000.00
NATH balance_sheet (annual, 2023-03-31) — Inventory: 539000.00
NATH balance_sheet (annual, 2023-03-31) — Invested Capital: 34486000.00
NATH cash_flow (annual, 2023-03-31) — Investing Cash Flow: -584000.00
NATH balance_sheet (annual, 2023-03-31) — Land And Improvements: 123000.00
NATH balance_sheet (annual, 2023-03-31) — Leases: 7392000.00
NATH balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 5406000.00
NATH balance_sheet (annual, 2023-03-31) — Long Term Debt: 79048000.00
NATH balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 84454000.00
NATH balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 5200000.00
NATH cash_flow (annual, 2023-03-31) — Net Common Stock Issuance: -1892000.00
NATH balance_sheet (annual, 2023-03-31) — Net Debt: 49187000.00
NATH income_statement (annual, 2023-03-31) — Net Income: 19623000.00
NATH income_statement (annual, 2023-03-31) — Net Income Common Stockholders: 19623000.00
NATH income_statement (annual, 2023-03-31) — Net Income Continuous Operations: 19623000.00
NATH income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: 19623000.00
NATH income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: 19623000.00
NATH cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: 19623000.00
NATH income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: 19623000.00
NATH income_statement (annual, 2023-03-31) — Net Interest Income: -7302000.00
NATH income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: -7302000.00
NATH cash_flow (annual, 2023-03-31) — Net Other Financing Charges: -30000000.00
NATH balance_sheet (annual, 2023-03-31) — Net PPE: 9742000.00
NATH cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -584000.00
NATH balance_sheet (annual, 2023-03-31) — Net Tangible Assets: -45526000.00
NATH balance_sheet (annual, 2023-03-31) — Non Current Deferred Assets: 375000.00
NATH balance_sheet (annual, 2023-03-31) — Non Current Deferred Liabilities: 1272000.00
NATH balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 375000.00
NATH income_statement (annual, 2023-03-31) — Normalized EBITDA: 36038000.00
NATH income_statement (annual, 2023-03-31) — Normalized Income: 19884324.00
NATH cash_flow (annual, 2023-03-31) — Operating Cash Flow: 19837000.00
NATH cash_flow (annual, 2023-03-31) — Operating Gains Losses: 444000.00
NATH income_statement (annual, 2023-03-31) — Operating Income: 34445000.00
NATH income_statement (annual, 2023-03-31) — Operating Revenue: 130785000.00
NATH balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 4079720.00
NATH balance_sheet (annual, 2023-03-31) — Other Current Assets: 468000.00
NATH balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 228000.00
NATH income_statement (annual, 2023-03-31) — Other Gand A: 14061000.00
NATH income_statement (annual, 2023-03-31) — Other Income Expense: -339000.00
NATH balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 869000.00
NATH cash_flow (annual, 2023-03-31) — Other Non Cash Items: 355000.00
NATH balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 168000.00
NATH balance_sheet (annual, 2023-03-31) — Other Non Current Liabilities: 737000.00
NATH income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 18000.00
NATH balance_sheet (annual, 2023-03-31) — Other Properties: 6421000.00
NATH balance_sheet (annual, 2023-03-31) — Other Receivables: 623000.00
NATH income_statement (annual, 2023-03-31) — Other Special Charges: 357000.00
NATH balance_sheet (annual, 2023-03-31) — Payables: 6537000.00
NATH balance_sheet (annual, 2023-03-31) — Payables And Accrued Expenses: 12957000.00
NATH balance_sheet (annual, 2023-03-31) — Prepaid Assets: 1203000.00
NATH income_statement (annual, 2023-03-31) — Pretax Income: 26804000.00
NATH balance_sheet (annual, 2023-03-31) — Properties: 0.00
NATH cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 457000.00
NATH cash_flow (annual, 2023-03-31) — Purchase Of PPE: -626000.00
NATH balance_sheet (annual, 2023-03-31) — Receivables: 15290000.00
NATH balance_sheet (annual, 2023-03-31) — Receivables Adjustments Allowances: -480000.00
NATH income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 81144000.00
NATH income_statement (annual, 2023-03-31) — Reconciled Depreciation: 1135000.00
NATH cash_flow (annual, 2023-03-31) — Repurchase Of Capital Stock: -1892000.00
NATH balance_sheet (annual, 2023-03-31) — Retained Earnings: -20559000.00
NATH cash_flow (annual, 2023-03-31) — Sale Of PPE: 42000.00
NATH income_statement (annual, 2023-03-31) — Selling General And Administration: 14061000.00
NATH balance_sheet (annual, 2023-03-31) — Share Issued: 9369235.00
NATH income_statement (annual, 2023-03-31) — Special Income Charges: -357000.00
NATH cash_flow (annual, 2023-03-31) — Stock Based Compensation: 258000.00
NATH balance_sheet (annual, 2023-03-31) — Stockholders Equity: -44562000.00
NATH balance_sheet (annual, 2023-03-31) — Tangible Book Value: -45526000.00
NATH income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: -95676.00
NATH income_statement (annual, 2023-03-31) — Tax Provision: 7181000.00
NATH income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.27
NATH balance_sheet (annual, 2023-03-31) — Taxes Receivable: 224000.00
NATH balance_sheet (annual, 2023-03-31) — Total Assets: 58610000.00
NATH balance_sheet (annual, 2023-03-31) — Total Capitalization: 34486000.00
NATH balance_sheet (annual, 2023-03-31) — Total Debt: 86236000.00
NATH balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: -44562000.00
NATH income_statement (annual, 2023-03-31) — Total Expenses: 96340000.00
NATH balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 103172000.00
NATH balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 11249000.00
NATH balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 86463000.00
NATH income_statement (annual, 2023-03-31) — Total Operating Income As Reported: 34445000.00
NATH balance_sheet (annual, 2023-03-31) — Total Tax Payable: 76000.00
NATH income_statement (annual, 2023-03-31) — Total Unusual Items: -357000.00
NATH income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: -357000.00
NATH balance_sheet (annual, 2023-03-31) — Treasury Shares Number: 5289515.00
NATH balance_sheet (annual, 2023-03-31) — Treasury Stock: 86662000.00
NATH balance_sheet (annual, 2023-03-31) — Working Capital: 30652000.00
NATH income_statement (annual, 2024-03-31) — +Operating Expense: 16747000.00
NATH income_statement (annual, 2024-03-31) — +Total Revenue: 138610000.00
NATH balance_sheet (annual, 2024-03-31) — Accounts Payable: 5744000.00
NATH balance_sheet (annual, 2024-03-31) — Accounts Receivable: 14972000.00
NATH balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -11687000.00
NATH balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 62936000.00
NATH income_statement (annual, 2024-03-31) — Basic Average Shares: 4081000.00
NATH income_statement (annual, 2024-03-31) — Basic EPS: 4.81
NATH cash_flow (annual, 2024-03-31) — Beginning Cash Position: 29861000.00
NATH balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 1414000.00
NATH cash_flow (annual, 2024-03-31) — Capital Expenditure: -313000.00
NATH balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 6824000.00
NATH balance_sheet (annual, 2024-03-31) — Capital Stock: 94000.00
NATH balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 21027000.00
NATH balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 21027000.00
NATH cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -8161000.00
NATH balance_sheet (annual, 2024-03-31) — Cash Equivalents: 11330000.00
NATH balance_sheet (annual, 2024-03-31) — Cash Financial: 9697000.00
NATH cash_flow (annual, 2024-03-31) — Cash Flow From Continuing Financing Activities: -28523000.00
NATH cash_flow (annual, 2024-03-31) — Cash Flow From Continuing Investing Activities: -313000.00
NATH cash_flow (annual, 2024-03-31) — Cash Flow From Continuing Operating Activities: 20002000.00
NATH cash_flow (annual, 2024-03-31) — Change In Account Payable: -1232000.00
NATH cash_flow (annual, 2024-03-31) — Change In Inventory: -303000.00
NATH cash_flow (annual, 2024-03-31) — Change In Other Current Assets: 27000.00
NATH cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 73000.00
NATH cash_flow (annual, 2024-03-31) — Change In Other Working Capital: -382000.00
NATH cash_flow (annual, 2024-03-31) — Change In Payable: -1232000.00
NATH cash_flow (annual, 2024-03-31) — Change In Payables And Accrued Expense: -1232000.00
NATH cash_flow (annual, 2024-03-31) — Change In Prepaid Assets: -281000.00
NATH cash_flow (annual, 2024-03-31) — Change In Receivables: -74000.00
NATH cash_flow (annual, 2024-03-31) — Change In Working Capital: -2172000.00
NATH cash_flow (annual, 2024-03-31) — Changes In Cash: -8834000.00
NATH balance_sheet (annual, 2024-03-31) — Common Stock: 94000.00
NATH cash_flow (annual, 2024-03-31) — Common Stock Dividend Paid: -8161000.00
NATH balance_sheet (annual, 2024-03-31) — Common Stock Equity: -32923000.00
NATH cash_flow (annual, 2024-03-31) — Common Stock Payments: 0.00
NATH balance_sheet (annual, 2024-03-31) — Construction In Progress: 0.00
NATH income_statement (annual, 2024-03-31) — Cost Of Revenue: 89357000.00
NATH balance_sheet (annual, 2024-03-31) — Current Accrued Expenses: 6025000.00
NATH balance_sheet (annual, 2024-03-31) — Current Assets: 38776000.00
NATH balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 1887000.00
NATH balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 1887000.00
NATH balance_sheet (annual, 2024-03-31) — Current Deferred Liabilities: 1702000.00
NATH balance_sheet (annual, 2024-03-31) — Current Deferred Revenue: 1375000.00
NATH balance_sheet (annual, 2024-03-31) — Current Liabilities: 15573000.00
NATH cash_flow (annual, 2024-03-31) — Deferred Income Tax: 165000.00
NATH cash_flow (annual, 2024-03-31) — Deferred Tax: 165000.00
NATH cash_flow (annual, 2024-03-31) — Depreciation Amortization Depletion: 1135000.00
NATH income_statement (annual, 2024-03-31) — Depreciation Amortization Depletion Income Statement: 1135000.00
NATH cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 1135000.00
NATH income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 1135000.00
NATH income_statement (annual, 2024-03-31) — Diluted Average Shares: 4087000.00
NATH income_statement (annual, 2024-03-31) — Diluted EPS: 4.80
NATH income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 19616000.00
NATH income_statement (annual, 2024-03-31) — EBIT: 32806000.00
NATH income_statement (annual, 2024-03-31) — EBITDA: 33941000.00
NATH cash_flow (annual, 2024-03-31) — End Cash Position: 21027000.00
NATH cash_flow (annual, 2024-03-31) — Financing Cash Flow: -28523000.00
NATH cash_flow (annual, 2024-03-31) — Free Cash Flow: 19689000.00
NATH cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: 0.00
NATH income_statement (annual, 2024-03-31) — General And Administrative Expense: 15612000.00
NATH balance_sheet (annual, 2024-03-31) — Goodwill: 95000.00
NATH balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 790000.00
NATH balance_sheet (annual, 2024-03-31) — Gross PPE: 20563000.00
NATH income_statement (annual, 2024-03-31) — Gross Profit: 49253000.00
NATH cash_flow (annual, 2024-03-31) — Income Tax Paid Supplemental Data: 8309000.00
NATH income_statement (annual, 2024-03-31) — Interest Expense: 5355000.00
NATH income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 5355000.00
NATH income_statement (annual, 2024-03-31) — Interest Income: 383000.00
NATH income_statement (annual, 2024-03-31) — Interest Income Non Operating: 383000.00
NATH cash_flow (annual, 2024-03-31) — Interest Paid Supplemental Data: 5477000.00